Literature DB >> 8016408

Evidence for the presence of prolyl oligopeptidase and its endogenous inhibitor in neonatal rat pancreatic beta-cells.

P Salers1.   

Abstract

Prolyl oligopeptidase (PE), an enzyme that may be involved in the maturation and degradation of hormones and neuropeptides has been detected in neonatal rat pancreatic islet cell monolayer cultures. PE activity was not observed in islet cell homogenates but when cellular extracts were subjected to gel-filtration, a such activity with a molecular mass about 70 kDa can be detected. Gel-filtration experiment has led to the finding of a PE inhibitor in these extracts with an estimated molecular mass of 6.5 kDa. After separation of the endogenous inhibitor from PE enzyme by gel-filtration, PE inhibitor was partially purified in a single activity peak by reverse-phase high-performance liquid chromatography (HPLC). It inhibited the fluorogenic substrate Z-Gly-Pro-beta Na degradation by partially purified PE in a competitive manner. Inhibitor is shown to be specific for PE enzyme and it is not released by potassium depolarization of islet cell membrane. These findings indicated that inhibitor is localized in the cytosolic compartment as prolyl oligopeptidase. The specific activity of the inhibitor in beta-cell cultures derived from donor rats varying from 3-20 days of age was unchanged. In contrast, PE inhibitor can only be detected in pancreatic tissue from 3-day-old rats compared with tissue from 20-day-old and adult rats after gel filtration. This discrepancy can be relevant to the different endocrine/exocrine tissue ratios in the pancreas during developing rats. Furthermore, pancreatic tissue from streptozotocin-treated 3-day-old rats did not show PE inhibitory activity indicating that PE inhibitor was principally contained in beta-cells. Based on the biochemical characteristics of the beta-cell PE inhibitor, the enhancement of PE activity observed in neonatal pancreas of STZ-treated rat as previously described (P. Salers, Regul. Pept., 50 (1994) 101-111), appears to be due to the presence of the endogenous PE inhibitor in neonatal rat pancreatic beta-cells that disappears following STZ-treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016408     DOI: 10.1016/0167-0115(94)90004-3

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  6 in total

1.  Distribution of immunoreactive prolyl oligopeptidase in human and rat brain.

Authors:  Timo T Myöhänen; Jarkko I Venäläinen; Erkki Tupala; J Arturo Garcia-Horsman; Riitta Miettinen; Pekka T Männistö
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

2.  Localization and subcellular distribution of prolyl oligopeptidase in the mouse placenta.

Authors:  Shin Matsubara; Takayuki Takahashi; Atsushi P Kimura
Journal:  J Mol Histol       Date:  2011-05-05       Impact factor: 2.611

3.  Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.

Authors:  Jofre Tenorio-Laranga; Francisco Coret-Ferrer; Buenaventura Casanova-Estruch; María Burgal; J Arturo García-Horsman
Journal:  J Neuroinflammation       Date:  2010-04-06       Impact factor: 8.322

4.  Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues.

Authors:  Timo T Myöhänen; Jarkko I Venäläinen; J Arturo García-Horsman; Marjo Piltonen; Pekka T Männistö
Journal:  Histochem Cell Biol       Date:  2008-07-11       Impact factor: 4.304

Review 5.  Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.

Authors:  Timo T Myöhänen; J Arturo García-Horsman; Jofre Tenorio-Laranga; Pekka T Männistö
Journal:  J Histochem Cytochem       Date:  2009-05-26       Impact factor: 2.479

6.  Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?

Authors:  Pekka T Männistö; J Arturo García-Horsman
Journal:  Front Aging Neurosci       Date:  2017-02-14       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.